Kornimate/medical-research-clean huggingface dataset:
the effects of vibration and kinesiology tape applications in children with hemiplegic cerebral palsy

Conditions: Hemiplegic Cerebral Palsy

Summary: the aim of this study was to evaluate the effects of vibration and kinesiology tape applications applied to the affected side forearm extensor muscles on dexterity in children with hemiplegic cerebral palsy.

upper extremity in children with hemiplegic cerebral palsy significantly more affected than the lower extremities. child mostly does not use the affected side and activity and weight uses the solid side in the overlay. in the upper extremity one of the muscles most affected by spasticity is the wrist and wrist. finger flexors. secondary in antagonist of these muscles weakness develops and posture disorders occur. in this study the kinesiology tape, which has been increasingly used in recent years, affected by the application and local vibration application. hand with application to the lateral forearm extensor muscle group comparing their effects on their skills with the control group. aimed to evaluate. as a result of the study, this diagnosis hand skills of which application in children who are studying has a greater effect on and in which rehabilitation that the application should be preferred more it will be a guide for physiotherapists.

Eligibility criteria:
inclusion criteria: * diagnosed with hemiplegic cerebral palsy, * no severe spasticity that prevents grasping and releasing an object (modified which is at the level of 0, 1, 1+, 2 according to the ashworth scale), * according to the hand skills classification system (ebss) at 1, 2 and 3 levels with function, * consisting of children between the ages of 4-18, * being treated in a special education and rehabilitation center, * the family accepts the participation of their child in the study. * they are children who have the mental level to take basic commands. exclusion criteria: * having severe mental retardation that prevents communication and taking basic commands, * the family does not accept the child to work, * severe spasticity that prevents grasping an object (modified ashworth 3 and 4 levels according to the scale), * hand function at 4 and 5 levels according to the hand skills classification system (ebss) the one which, * compliance and behavior during the application of the tests used to obtain the data are children with the disorder.

Keywords: cerebral palsy kinesio tape physiotherapy vibration
comorbidity management in rheumatic disease.

Conditions: Rheumatoid Arthritis; Comorbidities and Coexisting Conditions

Summary: rheumatoid arthritis is a disease where the immune system attacks the body by mistake, causing inflammation of the joints and other body parts. people with rheumatoid arthritis are at higher risk of infections, heart problems, and bone issues compared to others. they regularly see rheumatologists, arthritis care physicians, to manage their disease. however, managing these other health problems alongside their main treatment is difficult for rheumatologists due to limited resources. this clinical study is being conducted to see if adding a family doctor to a team of rheumatologists can help. rheumatologists will complete a case report form about the patient's health and send them to a special family physician clinic. this clinic will focus on improving vaccination against diseases, heart health, and bone strength. they will check if patients need special vaccines to protect them from infections. they will screen for heart disease using blood pressure measurements, and order blood work for high cholesterol and diabetes if needed. they will also review bone health and send people for tests to check their bone density if needed. a change in routines and medications may be recommended after their checkup. rheumatologists will complete another case report about the patient's health 6 months after their family doctor appointment. the study will assess how these markers of health management improve after this family doctor joins the team. it hopes to prove that this new way of working in the community will give people with rheumatoid arthritis better protection against certain infections, heart problems and weak bones.


Eligibility criteria:
inclusion criteria: participants will be patients of the waterloo rheumatology community clinic, aged 18 to 80 years of age, with a diagnosis of rheumatoid arthritis. participants will have a minimum of limited working proficiency in english and no significant cognitive impairment that can inhibit their ability to engage in the study. exclusion criteria: age less than 18 years or greater than 80 years, significant cognitive impairment that impedes ability to engage in the study or unwilling to participate in the study. patients that are currently pregnant will be excluded from the study as well. whether or not a participant is enrolled with a primary care physician or nurse practitioner will not impact the intervention.

Keywords: rheumatoid arthritis comorbidities
a multiple dose study of pf-06678552 in healthy subjects

Conditions: Healthy

Summary: pf-06678552 is a new compound proposed for the treatment of hypercholesteremia. the primary purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of pf-06678552 in healthy subjects.


Eligibility criteria:
inclusion criteria: * healthy male and/or female subjects of non-childbearing potential. * body mass index (bmi) of 18 to 30.5 kg/m2; and a total body weight \>50 kg * low density lipoprotein cholesterol between 115 mg/dl and 190 mg/dl exclusion criteria: * evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing)

Keywords: multiple ascending dose healthy subjects hypercholesterolemia hyperlipidemias dyslipidemias lipid metabolism disorders metabolic diseases
dose-ranging trial to evaluate delgocitinib cream 1, 3, 8, and 20 mg/g compared to delgocitinib cream vehicle over an 8-week treatment period in adult subjects with atopic dermatitis.

Conditions: Atopic Dermatitis

Summary: this is a double-blind, multi-centre, randomised, 5-arm, vehicle-controlled, parallel-group trial. the trial is designed to establish a dose-response signal and investigate the efficacy and safety of delgocitinib cream in the treatment of adult subjects with mild to severe atopic dermatitis (ad).


Eligibility criteria:
key inclusion criteria: * age 18 years and above. * diagnosis of ad as defined by the hanifin and rajka 1980 criteria for ad. * history of ad for ≥1 year. * ad involvement of 5-50% treatable body surface area at screening and at baseline (excluding scalp). * disease severity graded as mild to severe according to viga-ad (i.e. viga-ad ≥2) at screening and baseline. key exclusion criteria: * ad lesion(s) on scalp at screening and/or baseline. * active dermatologic conditions that may confound the diagnosis of ad or would interfere with assessment of treatment, such as scabies, cutaneous lymphoma, rosacea, urticaria, or psoriasis. * known active allergic or irritant contact dermatitis that is likely to interfere with the assessment of severity of ad. * use of tanning beds or phototherapy within 4 weeks prior to baseline. * systemic treatment with immunosuppressive/modulating drugs or corticosteroids within 4 weeks prior to baseline or 3 or more bleach baths any week within 4 weeks prior to baseline. * treatment with topical corticosteroids, topical calcineurin inhibitors, topical phosphodiesterase-4 inhibitors, or oral antibiotics within 2 weeks prior to baseline. * change in systemic antihistamine therapy within 2 weeks prior to baseline i.e. the subjects must not start antihistamine treatment or change the current dosage regime within 2 weeks prior to baseline. * receipt of live attenuated vaccines within 4 weeks prior to baseline. * treatment with any marketed or investigational biologic agents within 6 months or 5 half-lives prior to baseline, or until cell counts return to normal, whichever is longer. * history of any active skin infection within 1 week prior to baseline. * clinically significant infection (systemic infection or serious skin infection requiring parenteral treatment) within 4 weeks prior to baseline.
a drug-drug interaction study of orforglipron (ly3502970) in healthy overweight and obese participants

Conditions: Healthy; Obese; Overweight

Summary: the main purpose of this study is to determine effect of orforglipron capsule formulation on the amount of digoxin, rosuvastatin, acetaminophen, midazolam, and simvastatin (each given alone and together with orforglipron) that enters the bloodstream and how long it takes the body to eliminate them when administered orally in healthy overweight and obese participants. in addition, the effect of the orforglipron tablet on the amount of simvastatin that enters the bloodstream and how long it takes the body to eliminate it will be evaluated. the study will also assess the effect of sodium bicarbonate when administered alone with simvastatin versus orforglipron capsule containing sodium bicarbonate administered with simvastatin. the safety and tolerability of orforglipron and information about any side effects experienced will be collected. study will be conducted in two parts, with part 1 and 2 lasting up to approximately 23 and 24 weeks each, including the screening period.


Eligibility criteria:
inclusion criteria: * participants who are overtly healthy as determined by medical history and physical examination. * have body mass index (bmi) equal to or greater than 27 kilograms per meter squared (kg/m²), inclusive, at screening. * have an estimated glomerular filtration rate equal to or greater than 60 milliliters per minute (ml/min). * males and females who agree to follow contraceptive requirements, or women not of childbearing potential (wnocbp). * have venous access sufficient to allow for blood sampling. exclusion criteria: * have any type of diabetes with hemoglobin a1c (hba1c) level of 6.5 percent (%) or greater. * have significant history of or currently have major depressive disorder or psychiatric disorder within the last 2 years. * obesity induced by other endocrine disorders, such as cushing's syndrome or prader-willi syndrome. * have known clinically significant gastric emptying abnormality. * have undergone bariatric surgery (for example: lap-band, gastric bypass) * have a known self or family history (first-degree relative) of multiple endocrine neoplasia type 2a or type 2b, thyroid c-cell hyperplasia, or any form of thyroid cancer. * have an abnormal 12-lead electrocardiogram (ecg) at screening. * have significant previous or current history of comorbidities capable of significantly altering the absorption, metabolism, or elimination of drug. * participants must not be currently participating in or completed a clinical trial within the last 90 days. * have a known allergy or hypersensitivity to midazolam, simvastatin, rosuvastatin, or digoxin.
study to determine if using ventilation during open heart surgery improves lung outcomes

Conditions: Coronary Artery Disease; Heart Failure

Summary: to demonstrate that using continuous mechanical lung ventilatory support in combination with positive end expiratory pressure (peep)during open heart surgery will improve lung function and decrease lung complications after surgery.

this is a prospective, randomized, blinded study with a control group. the study group will receive mechanical ventilatory support during cbb, which consists of a preset/predetermined tidal volume, respiratory rate, positive pressure at the end of expiration and fio2. the control group will receive cpb without additional mechanical ventilatory support during surgery, which at present is the standard of care. the difference between the study and the control group will occur during the time the heart is arrested and the lungs, under present standard of care, are no longer ventilated. it is at this point in time that those in the study group will continue to receive ventilation, intermittent positive pressure ventilation, while their heart is arrested. the subjects will have their lungs ventilated six times per minute with a tidal volume equal to 7-10 milliliters per kilogram. this range, when combined with a consistent peep of 5cm of water pressure, will allow for the peak inspiratory pressure to be maintained at or below 40cm of water pressure. in addition, the fio2 will remain consistent at the same level that was needed to maintain the pulse oximetry at 94% as well as the end-tidal co2 at 35mmhg. the values mentioned for this study have been chosen based on not only investigator preference, but also on what is considered "minimally necessary" to prevent atelectasis. multiple studies have been done utilizing peep at 5 and 10 cm of water pressure. with the exception of the potential for mechanical ventilation during the cbp, the care of the subject, regardless of the group randomized into, will be the same. we will in all other aspects continue to utilize the current standard of care.

Eligibility criteria:
inclusion criteria: * any patient of any gender, any age with known coronary artery disease that will undergo elective coronary artery bypass grafting (cabg) and will require cpb as part of his/her operative technique. exclusion criteria: * documented ejection fraction (either by echocardiogram or by cardiac catheterization) equal to or below 20% * patients with cardiac valvular disease * patients with a spirometry measurement that demonstrates an fev1/fvc ratio below 60% * patients with chronic renal failure who require dialysis or * those who have experienced an allergic reaction to anesthesia in the past * patients with a history of lung infiltrate on chest x-ray prior to surgery or a history of asthma * women who are pregnant are excluded

Keywords: cardiopulmonary bypass surgery cabg peep
birth weight effect on blood pressure in late childhood

Conditions: Cardiovascular Diseases; Heart Diseases; Hypertension

Summary: to investigate the relationship of birth weight and childhood blood pressure.

background: cardiovascular diseases are the leading causes of morbidity and mortality in the united states. on the basis of an interplay of genetic and environmental factors, these diseases appear to be rooted in childhood. recent reports implicate the intrauterine nutritional environment regulating fetal growth as a determinant of adult cardiovascular disease. according to this concept, impaired fetal growth, with consequent lower birth weight, results in alteration in organ structure and subsequent functional impairment in later life. higher blood pressure (bp) has been suggested as the possible link between compromised intrauterine growth and the long-term risk for cardiovascular disease. despite the many reports which appear to support the low birth weight - high bp hypothesis, this concept is in conflict with the body of data on the association of bp with body size in childhood, adolescence, and adulthood which consistently demonstrates a direct relationship between body weight and bp. the results of this prospective study contributed an objective body of data to this important issue. if birth measures reflecting intrauterine exposure do contribute significantly to bp in later childhood, then studies focused on the mechanisms regulating this risk are justified. alternatively, if post-natal/childhood parameters are the major determinants of later bp, then efforts should focus on effective preventive strategies in childhood, such as obesity. design narrative: to examine the low birth weight - high blood pressure concept, the investigators conducted a prospective study on a cohort of children who were well characterized at birth. in 1988, data on weight, length, bp, gestation and maternal health were obtained on 1,160 newborn cases representing a range of birth weight and gestational age. they re-examined these children at age 11-13 years to test the overall hypothesis that birth weight, as well as other newborn measures of intrauterine growth, did not correlate with bp at age 11-13 years. the aims of the project were to: 1) determine if birth weight contributed to bp and/or body size in childhood; 2) determine if the duration of intrauterine growth in terms of gestational age contributed to bp and body size; 3) determine if newborn ponderal index, a measure of relative fetal growth, contributed to bp and body size; and 4) determine the relative contribution of newborn measures of birth weight, gestational age, bp, ponderal index, and maternal health to bp and body size in late childhood. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
defibrotide in children with high risk kawasaki disease

Conditions: Kawasaki Disease

Summary: this study evaluates the safety of defibrotide with ivig in children with high risk kawasaki disease.


Eligibility criteria:
inclusion criteria: * kawasaki disease presumptive diagnosis defined according aha criteria; * signed informed consent and patient assent (if applicable) * diagnosis of kd and initiation of defibrotide within 96 hours from the conclusion of ivig treatment * age: 0 - 11 years old * high risk category defined as patient meeting ≥2 of the following criteria: male, age \ 8yrs, ivig-resistance, fever lasting greater than 10 days, prior to diagnosis, coronary artery aneurysms, and/or laboratory tests indicating worse systemic inflammation * pt and ptt within institutional normal limits * platelet count ≥100,000/mm3 exclusion criteria: * history of grade iii or iv hemorrhage or active bleeding; * previous grade ii-iv hypersensitivity to defibrotide * current systemic anti-coagulant therapy and/or fibrinolytic therapy, excluding aspirin (5 mg/kg/dose maximum). * patients on an active experimental trial for kawasaki disease

Keywords: kawasaki children defibrotide
fuzeon viral decay pilot study

Conditions: HIV-1

Summary: in order to better understand the source(s) and the mechanism(s) of hiv persistence and to potentially lead to further suppression of hiv from viral reservoirs, we propose to examine the effect of co-administration of enfuvirtide, an entry inhibitor of hiv, on diminution of the size of the viral reservoir in infected individuals who are receiving effective antiviral therapy for extended periods of time (\> 5 years).


Eligibility criteria:
inclusion criteria: 1. patient must be hiv infected 2. patient must be \> 18 years old 3. patient must be taking standard combination antiretroviral therapy with 2-3 nrtis and 1-2 pis or a nnrtis for at least five years 4. patient must have a viral load \< 50 copies/ml (using the standard available methods of detection) during the entire time on standard combination antiretroviral therapy except for initial fall of viral load 5. patient must have a cd4 count above 400 cells/mm3 in last 3 months 6. female patient must agree to use two methods of birth control or abstinence during the period of the study 7. patient has to have signed full informed consent exclusion criteria: 1. patient who would have difficulty participating in a trial due to non-adherence or substance abuse 2. patient who have taken mono or dual antiretroviral therapy 3. patient who have had a viral load \> 50 copies/ml on any antiretroviral regimen 4. patient with any of the following abnormal laboratory test results in screening: * hemaglobin \< 100 g/l * neutrophil count \< 750 cells/ul * platelet count \< 50,000 cells/l * ast or alt \> 5x the upper limit of normal * creatinine \> 250 umol/l 5. patient with a malignancy 6. patient with other significant underlying disease (non-hiv) that might impinge upon disease progression or death 7. patient with an active aids-defining illnesses in the past six months 8. patients who are pregnant

Keywords: fuzeon viral decay
pulmonary nodule cohort

Conditions: Pulmonary Nodule, Solitary; Lung Cancer

Summary: the aim of this study is to identify the clinical features of pulmonary nodules and establish a cohort to identify biomarkers for lung cancer.


Eligibility criteria:
inclusion criteria: * age \>= 18 * pulmonary nodule(s) on chest ct, which satisfy at least one of the following two criteria, * 4a or above in lung-rads v1.1 * lung cancer risk \>= 5% in brock model exclusion criteria: * already proven lung cancer
comparative bioequivalence study in adult patients suffering from chronic myeloid leukemia & gastrointestinal stromal tumor under fed conditions

Conditions: Chronic Myeloid Leukemia; Gastrointestinal Stromal Tumor

Summary: to characterize pharmacokinetic profile of test product compared to that of the corresponding reference product in adult patients, who are diagnosed to have chronic myeloid leukemia \& gastrointestinal stromal tumor under fed conditions.

to characterize pharmacokinetic profile of imatinib mesylate tablets eq 400 mg base of amneal pharmaceuticals llc, compared to that of the reference product - gleevec® (imatinib mesylate) tablets 400 mg in adult patients, who are diagnosed to have cml or gist and are presently receiving stable dose of imatinib mesylate tablets 400 mg, and assess their bioequivalence.

Eligibility criteria:
inclusion criteria: * age 18 to 55 years (both inclusive) and either sex * diagnosed case of philadelphia chromosome positive (ph+) cml patients in chronic phase or gist and presently being treated with imatinib 400 mg tablets. * willing to give written informed consent for participation in the study as well as willing and able to comply with study visit schedule and other protocol requirements. * female patients of child bearing potential (except for those who have completed one year since menopause or have gone through hysterectomy or bilateral tubal ligation) must have negative serum pregnancy test at the screening, negative urine pregnancy test on check in to housing, must be non-lactating at screening and must agree to use effective contraception (barrier or hormonal) for the study period. exclusion criteria: * history of hypersensitivity to imatinib mesylate or to any of the excipients as judged by investigator. * patient of cml receiving treatment in myeloid blast crisis or accelerated phase * abnormal laboratory results as below: * history of a heart failure, renal insufficiency, hypereosinophilic syndrome (hes), myelodysplastic syndrome (mds)/ myeloproliferative disease (mpd) or acute systemic mastocytosis (asm). * history of therapy with any of the following as per timelines before randomization: inducers of cyp3a4 activity and inhibitors of cyp3a4 activity, within 14 days, investigational product/device within last one month * alcohol or any drug dependence within past one year. * blood donation/loss exceeding 200 ml within last 60 days.